Shopping Cart
- Remove All
- Your shopping cart is currently empty
JTK-853 is a novel, non-nucleoside inhibitor of Hepatitis C Virus (HCV) polymerase, exhibiting effective antiviral activity in HCV replicon cells with EC50s of 0.38 μM for genotype 1a H77 strain and 0.035 μM for genotype 1b Con1 strain.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $4,859 | 8-10 weeks | |
50 mg | $6,318 | 8-10 weeks | |
100 mg | $8,219 | 8-10 weeks |
Description | JTK-853 is a novel, non-nucleoside inhibitor of Hepatitis C Virus (HCV) polymerase, exhibiting effective antiviral activity in HCV replicon cells with EC50s of 0.38 μM for genotype 1a H77 strain and 0.035 μM for genotype 1b Con1 strain. |
Targets&IC50 | HCV 1b Con1:0.035 μM, HCV 1a H77:(EC50)0.38 μM |
In vitro | JTK-853 inhibits the drug-resistant colony formation in the genotype 1a replicon cells, and the numbers of JTK-853-resistant colonies are much lower than those of GS-9190-resistant colonies for both genotypes. When JTK-853 is incubated with the replicon cells for 48 h, it shows antiviral activity against genotype 1a H77 and 1b Con1 replicon cells (EC90: 6.5±0.5 and 0.34±0.05 μM, respectively). In 2-week culture, JTK-853(at 10 μM) causes apparent Huh-7.5 cell death[1]. |
Molecular Weight | 704.64 |
Formula | C28H23F7N6O4S2 |
Cas No. | 954389-09-4 |
Relative Density. | 1.565 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.